FDA NDC Directory · JSON-LD · Markdown

Kanjinti

NDC 55513-132 · HUMAN PRESCRIPTION DRUG · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Generic nametrastuzumab-anns
Labeler / ManufacturerAmgen, Inc
Marketing categoryBiologic License Application · App BLA761073
Dosage form / routeINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · INTRAVENOUS
Active ingredientsTRASTUZUMAB (420 mg/20mL)
Marketing started20190611
Package count2

External sources

Source: openFDA. Public-domain (CC0).